Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients: A meta-analysis of randomized controlled trials

Journal of Biomedical Research

Volumn 29, Issue 6, 2015, Pages 475-485

  Zhao, Di ^a   Wang, Ze Mu ^a   Wang, Lian Sheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitors; Atrial fibrillation; Hypertension; Meta analysis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; ATRIAL FIBRILLATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84959121480     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.29.20140149     Document Type: Article

References (22)

1. Kotwani P, KwarisiimaD, Clark TD, et al. Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study[J]. BMC Public Health, 2013, 13(1):1151.
2. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study[J]. Am J Med 1995, 98(5):476-484.
3. New approaches to antiarrhythmic therapy, part II: emerging therapeutic applications of the cell biology of cardiac arrhythmias[J]. Circulation, 2001, 104(24):2990-2994.
4. Makkar KM, Sanoski CA, Spinler SA. Role of angiotensin- converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias[J]. Pharmacotherapy, 2009, 29(1):31-48.
5. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis[J]. Am J Therb, 2008, 15(1):36-43.
6. Anand K, Mooss AN, Hee TT, et al. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation[J]. Am Heart J, 2006, 152(2):217-222.
7. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis[J]. J Am Coll Cardiol, 2005, 45(11):1832-1839.
8. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses[J]. BMJ, 2003, 327(7414):557-560.
9. Armitage P, Berry G, Matthews JNS. Analysing Means and Proportions. Statistical Methods in Medical Research[J]. Blackwell Science Ltd 2008:83-146.
10. WachtellK, LehtoM, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study[J]. J Am Coll Cardiol, 2005, 45(5):712-719.
11. Yamashita T, Inoue H, Okumura K, et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study)[J]. Europace, 2011, 13(4):473-479.
12. Du H, Fan J, Ling Z, et al. Effect of nifedipine versus telmisartan on prevention of atrial fibrillation recurrence in hypertensive patients[J]. Hypertension, 2013, 61(4):786-792.
13. Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients[J]. J Cardiovasc Pharmacol, 2006, 47(1):46-50.
14. Fogari R, Derosa G, Ferrari I, et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation[J]. Am J Hypertens, 2008, 21(9):1034-1039.
15. Fogari R, Zoppi A, Maffioli P, et al. Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size[J]. Clin Cardiol, 2012, 35(6):359-364.
16. Galzerano D, Di Michele S, Paolisso G, et al. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients[J]. J Renin Angiotensin Aldosterone Syst, 2012, 13(4):496-503.
17. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients:cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study[J]. Lancet, 1999, 354(9192):1751-1756.
18. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial[J]. Lancet, 2004, 363(9426):2022-2031.
19. Hansson L, LindholmLH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial[J]. Lancet, 1999, 353(9153):611-616.
20. Schmieder RE, Kjeldsen SE, Julius S, et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial[J]. J Hypertens, 2008, 26(3):403-411.
21. Huang G, Xu JB, Liu JX, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a metaanalysis[ J]. Eur J Clin Invest, 2011, 41(7):719-733.
22. Han M, Zhang Y, Sun S, et al. Renin-Angiotensin System Inhibitors Prevent the Recurrence of Atrial Fibrillation:A Meta-Analysis of Randomized Controlled Trials[J]. J Cardiovasc Pharmacol, 2013, 62(4):405-415.